DNX-2401 adenovirus: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

5 April 2024

  • curprev 20:1820:18, 5 April 2024‎ Lazy talk contribs‎ 824 bytes +824‎ Created page with " {{TreatmentInfo |drug_name=DNX-2401 adenovirus |category=Oncolytic virotherapy |book_text=Another viral therapy in phase 1 has had impressive results, comparable to the PVS-RIPO trial. DNX-2401 is a modified adenovirus that is directly injected into the tumor. Preliminary results of a phase 1 trial at MD Anderson in Houston, Texas were presented at the November 2014 SNO conference in Miami. 37 recurrent high-grade glioma patients had been treated, with no adverse event..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=DNX-2401_adenovirus"